Effectiveness of Yiqi Chupi powder for alleviating cancer-related fatigue in patients following colorectal cancer surgery: a randomized controlled trial.
Hao Shulan, Nan Peng, Liu Likun, L I Xiaoli, Zhong Qiming, Gao Yu, Wang Xixing, Nie Yingfang
{"title":"Effectiveness of Yiqi Chupi powder for alleviating cancer-related fatigue in patients following colorectal cancer surgery: a randomized controlled trial.","authors":"Hao Shulan, Nan Peng, Liu Likun, L I Xiaoli, Zhong Qiming, Gao Yu, Wang Xixing, Nie Yingfang","doi":"10.19852/j.cnki.jtcm.2025.05.017","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy of Yiqi Chupi powder (, YQCPP) in reducing cancer-related fatigue (CRF) among patients with colorectal cancer (CRC) undergoing chemotherapy.</p><p><strong>Methods: </strong>This was a prospective, randomized controlled trial. Eligible patients were randomly assigned to either the experimental group, receiving a 12-week regimen of YQCPP and capecitabine plus oxaliplatin (XELOX) chemotherapy, or the control group, receiving a 12-week XELOX chemotherapy alone. Outcome measures were collected at baseline and subsequently at weeks 3, 6, 9, and 12 of the treatment period. The primary outcome was the Piper Fatigue Scale (PFS) score. The secondary outcomes were the Traditional Chinese Medicine syndrome and Karnofsky Performance Status (KPS) scores.</p><p><strong>Results: </strong>Of 84 patients initially enrolled, 78 (92.9%) were evaluable. The experimental group exhibited significantly lower PFS scores (<i>P <</i>0.05) compared to the control group across all four subscales and total scores at 6, 9, and 12 weeks (<i>P <</i> 0.05). Additionally, the experimental group achieved a significantly higher effective rate (84.0% <i>vs</i> 7.89%, <i>P <</i> 0.05). The number of patients in the experimental group with improved or stable KPS scores increased significantly over the course of the treatment period in comparison to the control group (<i>P <</i>0.05) at 6, 9, and 12 weeks. There was a significant improvement in overall quality of life at weeks 9 and 12 in the experimental group.</p><p><strong>Conclusion: </strong>YQCPP may decrease the CRF and improve quality of life in patients with CRC undergoing chemotherapy.</p>","PeriodicalId":94119,"journal":{"name":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","volume":"45 5","pages":"1119-1126"},"PeriodicalIF":0.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454259/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19852/j.cnki.jtcm.2025.05.017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To evaluate the efficacy of Yiqi Chupi powder (, YQCPP) in reducing cancer-related fatigue (CRF) among patients with colorectal cancer (CRC) undergoing chemotherapy.
Methods: This was a prospective, randomized controlled trial. Eligible patients were randomly assigned to either the experimental group, receiving a 12-week regimen of YQCPP and capecitabine plus oxaliplatin (XELOX) chemotherapy, or the control group, receiving a 12-week XELOX chemotherapy alone. Outcome measures were collected at baseline and subsequently at weeks 3, 6, 9, and 12 of the treatment period. The primary outcome was the Piper Fatigue Scale (PFS) score. The secondary outcomes were the Traditional Chinese Medicine syndrome and Karnofsky Performance Status (KPS) scores.
Results: Of 84 patients initially enrolled, 78 (92.9%) were evaluable. The experimental group exhibited significantly lower PFS scores (P <0.05) compared to the control group across all four subscales and total scores at 6, 9, and 12 weeks (P < 0.05). Additionally, the experimental group achieved a significantly higher effective rate (84.0% vs 7.89%, P < 0.05). The number of patients in the experimental group with improved or stable KPS scores increased significantly over the course of the treatment period in comparison to the control group (P <0.05) at 6, 9, and 12 weeks. There was a significant improvement in overall quality of life at weeks 9 and 12 in the experimental group.
Conclusion: YQCPP may decrease the CRF and improve quality of life in patients with CRC undergoing chemotherapy.
目的：评价益气出脾散（YQCPP）减轻结直肠癌（CRC）化疗患者癌相关性疲劳（CRF）的疗效。方法：前瞻性、随机对照试验。符合条件的患者被随机分配到实验组，接受为期12周的YQCPP和卡培他滨加奥沙利铂（XELOX）化疗方案，或对照组，接受单独12周的XELOX化疗方案。在基线以及治疗期的第3、6、9和12周收集结果测量值。主要观察指标为Piper疲劳量表（PFS）评分。次要指标为中医证候和KPS评分。结果：84例初始入组患者中，78例（92.9%）可评估。与对照组相比，实验组在所有四个分量表上的PFS评分和6、9和12周的总分均显著低于对照组（P 0.05）。实验组有效率高于对照组（84.0% vs 7.89%, P < 0.05）。与对照组相比，实验组KPS评分改善或稳定的患者数量在治疗期间显著增加（P < 0.05），分别为6、9和12周。在第9周和第12周，实验组的整体生活质量有显著改善。结论：YQCPP可降低结直肠癌化疗患者的CRF，提高患者的生活质量。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
